IL-2 RECEPTOR--A TARGET FOR ANTIHORMONE THERAPY

IL-2 受体——抗激素治疗的靶点

• 批准号: 2105985
• 负责人: W D HANKINS
• 金额: $ 7.95万
• 依托单位: PROED, INC.
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-09-10 至 1995-03-09
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2105985
• 关键词: T lymphocyte; animal tissue; biomaterial development /preparation; cytokine receptors; hormone related neoplasm /cancer; human tissue; immunoconjugates; interleukin 2; iodine; lymphocytic leukemia; protein purification; radionuclides; radiotracer; recombinant proteins; tissue /cell culture; yttrium

DESCRIPTION: This Phase I proposal is designed to test feasibility of developing immunotoxins for human lymphoid leukemia using IL-2 and either 90Y or 131I. There is ample evidence that many cases of human leukemia are cytokine-dependent. The Principal Investigator has long experience in the study of erythropoietin-dependent erythroleukemia induced by Friend's spleen focus forming virus. Recently, several clinical trials have already established the efficacy of immunotoxin approach in certain malignancies and other diverse conditions such as autoimmune disorders and graft vs. host diseases. In this application, Dr. Hankin's proposes to test bioactivity of human recombinant prepare and purify 131I-IL-2, prepare and purify 90Y-IL-2, analyze the radiolabeled IL-2 compounds and test specificity of the compounds using cell lines that are dependent on other cytokines.He will also test the effects on primary murine and human T-cells.

描述：本阶段提案旨在测试以下项目的可行性 利用IL-2或两者之一开发人淋巴细胞性白血病免疫毒素 90Y或131I。有充分的证据表明，许多人类白血病病例 依赖于细胞因子。首席调查员有很长的经验 促红细胞生成素依赖性红白血病的研究进展 朋友的脾病灶形成病毒。最近，几项临床试验 已经确定了免疫毒素方法在某些方面的有效性 恶性肿瘤和其他各种疾病，如自身免疫性疾病 移植物对抗宿主疾病。在这份申请中，汉金博士提出了 为检测重组人131I-IL-2的生物活性，制备和纯化131I-IL-2， 制备和纯化90Y-IL-2，分析放射性标记的IL-2化合物和 用依赖于细胞的细胞系测试化合物的特异性 其他细胞因子。他还将测试对原代小鼠和 人类T细胞。